News

FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients

The U.S. Food and Drug Administration today approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first FDA approval of a drug to treat MS in pediatric patients.

“For the first time, we have an FDA-approved treatment specifically for children and adolescents with multiple sclerosis,” said Billy Dunn, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “Multiple sclerosis can have a profound impact on a child’s life. This approval represents an important and needed advance in the care of pediatric patients with multiple sclerosis.” to read the entire article click here:https://www.fda.gov/news-events/press-announcements/fda-expands-approval-gilenya-treat-multiple-sclerosis-pediatric-patients

 

UVa identifies surprising contributor to multiple sclerosis

School of Medicine researchers Megan S. Chappell, Alban Gaultier and Anthony Fernandez-Castaneda have identified a surprising contributor to multiple sclerosis that could lead to new treatments for the condition and possibly help doctors promote brain repair after injury.

Previously ignored cells are key contributors to multiple sclerosis, according to new research from the University of Virginia.

School of Medicine researchers were trying to establish the beneficial aspects of cells known as oligodendocyte progenitor cells, which make up about 5% of the brain and spinal cord and were thought to protect the myelin sheath that surrounds nerve cells.

In fact, they learned, progenitor cells contribute to the immune system’s attack on healthy cells during neurological diseases such as MS. To read the complete article click here: https://www.roanoke.com/news/uva-identifies-surprising-contributor-to-multiple-sclerosis/article_9a5e4405-eab7-592f-9f27-c2825099f73c.html

 

Bowel, Bladder Problems Linked to Higher Levels of Fatigue and Disability, Study Reports

Bladder and bowel problems, such as constipation and fecal incontinence, are associated with a higher level of fatigue in people with multiple sclerosis (MS), according to a study in Australia. The findings also showed that greater fatigue and experiencing bowel and bladder problems are associated with a higher level of disability. The research, “The frequency of bowel and bladder problems in multiple sclerosis and its relation to fatigue: A single center experience,” was published in the journal PLOS ONE. Bladder or bowel problems are frequent in people with MS, and may manifest as urinary incontinence or retention, slow intestinal transit, and chronic constipation. it is estimated that more than 50% of MS patients experience these problems. However, research on bowel dysfunction specifically, and on whether bladder and bowel symptoms are associated with fatigue and disability in MS, remain scarce. Now, a team at Neuroscience Research Australia conducted a single-center study to address these gaps. To continue to read more on this study refer to: Multiple Sclerosis News Today. com

FDA Approves Siponimod (Mayzent) for Multiple Sclerosis

The US Food and Drug Administration (FDA) has approved siponimod (Mayzent, Novartis) to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive (SP) disease, the agency announced.

Approval was based on results of the phase 3 trial, which randomly assigned 1651 patients with SPMS and an Expanded Disability Status Scale score of 3.0 to 6.5 to oral siponimod 2 mg once daily (1105 patients) or placebo (546 patients) for up to 3 years or until the occurrence of a prespecified number of confirmed disability progression events.

For most people, MS starts with a relapsing-remitting course, in which episodes of worsening function (relapses) are followed by recovery periods (remissions). These remissions may not be complete and may leave patients with some degree of residual disability. Many, but not all, patients with MS experience some degree of persistent disability that gradually worsens over time. In some patients, disability may progress independent of relapses, a process termed secondary progressive multiple sclerosis (SPMS).  In the first few years of this process, many patients continue to experience relapses, a phase of the disease described as active SPMS. Active SPMS is one of the relapsing forms of MS, and drugs approved for the treatment of relapsing forms of MS can be used to treat active SPMS. Later, many patients with SPMS stop experiencing new relapses, but disability continues to progress, a phase called non-active SPMS. To read more on this subject and review details on the trail performed, click here http://www.medscape.com And for additional information, click here https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm634469.htm

MS Alliance Of Virginia Presents Family Halloween Party

MS Alliance of Virginia Presents —  Hocus Pocus Family Halloween Party

Fun for everyone whose life has been affected by Multiple Sclerosis, Including caregivers , family and friends.  Come Enjoy Pizza, Games, Contests, Crafts and Music. Safe Halloween Fun For All.

WHEN: Saturday, October 26, 2019….. 6:00 p.m. – 10:00 p.m.

WHERE: Holiday Inn – Tanglewood

COSTS: FREE

CONTESTS INCLUDE: Costume – Adults and Kids, Food – Bring your Favorite Treat, Spooky or Not, And Cupcake Decorating.

 

Muse Ball Field Music Festival

MUSE BALL FIELD MUSIC FESTIVAL

Featuring: Music, Food Trucks, Concessions, Car Show, 50/50 Raffle, Silent Auction, and More !!!!

Event Is this – Saturday, September 14th, 2019,  3:00 p.m. – 7:00 p.m.

Admission: $5 Donation to Multiple Sclerosis Alliance of Virginia

(Please make checks out to Multiple Sclerosis Alliance of Virginia)

Please bring your Lawn Chairs, Blankets, and / or Tents

Location: 365 Muse Field Road, Rocky Mount, Va 24151

NO ALCOHOLIC BEVERAGES

All Proceeds to benefit the Multiple Sclerosis Alliance of Virginia

Coping With Anxiety in Multiple Sclerosis

Multiple Sclerosis is a disease that has both physical and emotional symptoms. Emotional symptoms such as stress, anxiety, worry, fear, frustration, and depression are common, and can be both a reaction to the disease and a symptom of the disease. Additional reasons why an individual with MS may have neuropsychiatric symptoms include the MS disease course, a reaction to a disease-modifying therapy, or a biologically mediated reaction / pathophysiology. This article addresses five ways to deal with emotional stress. To read this article in its entirely start on page 26 at http://msfocusmagazine.org

Taking Care of Your Emotional Wellness

Living with MS can definitely take a toll on your mood and emotional health. Often, people living with MS experience the loss of the person they were prior to the diagnosis, their social / familiar / professional roles, and physical ability. Frustration can become a recurring feeling when faced with the daily reminder of physical and cognitive challenges or the changes that have occurred over time. Questions about the future cause worry about what will happen next. To read the rest of this article with some great ideas, to address this issue read more starting on page 12 at http://msfocusmagazine.org

Experimental Medication Evobrutinib (M2951) Shown to Reduce Number of Lesions

Evobrutinib (M2951) is a oral medication being evaluated for potential use in relapsing forms of multiple sclerosis and in secondary-progressive MS. The agent inhibits Bruton’s tyrosine kinase (BTK), an enzyme that regulates the function of B cells and macrophages, components of the immune system shown to play a role in MS.

A recent Phase 2 study examined how various doses of evobrutinib affected the total number of T1 gadolonium-enhancing lesions seen on magnetic resonance imaging (MRI) at weeks 12, 16, 20, and 24 of trearment. The study also assessed safety, the annualized relapse rate (ARR), and MRI findings at week 24 and 48 to read more on this click here https://mymsaa.org/news/new-in-ms-research-july-2019/#7

Cannabidiol-based Oral Treatment Seen to Promote Remyelination in Mice

EHP-101, a cannabidiol-based experimental therapy for multiple sclerosis, was able to recover myelin in damaged nerve fibers and lessen neuroinflammation in a mouse model of MS, data show.

Emerald Health Therapeutics, the manufacturer of EHP-101 also announced plans to open Phase 2 clinical trials in patients by the close of this year.

The data on EHP-101 were shared at the 29th Annual Symposium of the International Cannabinoid Research Society (ICRS), Held June 30 – July 3 in Maryland, and suggest that EHP_101 may be a potential remyelination therapy. Click on the link to find the rest of this article at http://multiplesclerosisnewstoday.com  released on July 9th, 2019, By Ana Pena